Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 73Neoplasms 46Squamous Cell Carcinoma of Head and Neck 45Head and Neck Neoplasms 35Lung Neoplasms 34Uterine Cervical Neoplasms 27Neoplasm Metastasis 26Unspecified Adult Solid Tumor, Protocol Specific 24Stomach Neoplasms 24Ovarian Neoplasms 24Small Cell Lung Carcinoma 21Pancreatic Neoplasms 19Colorectal Neoplasms 18Cholangiocarcinoma 17Carcinoma, Squamous Cell 17Esophageal Neoplasms 16Breast Neoplasms 15Mesothelioma, Malignant 14Melanoma 13Urinary Bladder Neoplasms 12Mesothelioma 11Fallopian Tube Neoplasms 11Carcinoma, Ovarian Epithelial 11Sarcoma 9Gallbladder Neoplasms 9Esophageal Squamous Cell Carcinoma 9Biliary Tract Neoplasms 9Carcinoma 8Triple Negative Breast Neoplasms 7Recurrence 7

Interventions

Ipilimumab 10Nivolumab 9Interleukin-2 5Cyclophosphamide 5pembrolizumab 3incomplete Freund's adjuvant 3fludarabine phosphate 3Radiosurgery 3Melphalan 3ADI PEG20 3sotrastaurin 2fludarabine 2Specimen Handling 2Ranibizumab 2Magnetic Resonance Spectroscopy 2MART-1 Antigen 2CTLA-4 Antigen 2Biopsy 2utomilumab 1tocilizumab 1siremadlin 1sargramostim 1ruxolitinib 1relatlimab 1pentetreotide 1obinutuzumab 1montanide ISA 51 1lifileucel 1gp100 Melanoma Antigen 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Uveal Melanoma × Cisplatin × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡